ProKidney Corp. Class A Ordinary Shares (PROK) Stock
NASDAQ · PROK
Key stats
- Market cap
- $236.14M
- Price / Earnings ratio
- -4.0x
- EPS (TTM)
- -$0.55
- Volume
- Loading
- 52-week high
- $2.88
- 52-week low
- $0.87
Source: third-party data provider, as of November 13, 2026
Compare with PROK
Recent news

Zacks Investment Research
ProKidney Corp. (PROK) Reports Q2 Loss, Misses Revenue Estimates
PROKAugust 10, 2026
Zacks Investment Research
ProKidney Corp. (PROK) Reports Q2 Loss, Misses Revenue Estimates
PROK

Zacks Investment Research
ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates
PROKMay 15, 2026
Zacks Investment Research
ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates
PROK

Zacks Investment Research
Best Momentum Stocks to Buy for July 17th
PROKJuly 17, 2025
Zacks Investment Research
Best Momentum Stocks to Buy for July 17th
PROK

Zacks Investment Research
New Strong Buy Stocks for July 17th
PROKJuly 17, 2025
Zacks Investment Research
New Strong Buy Stocks for July 17th
PROK
Technical indicators
- RSI 14
- 36.51
- MACD 12/26/9
- -0.13
- EMA 9 of MACD
- -0.12
- MACD histogram
- -0.01
- SMA 50
- $1.56
- Price below SMA 50
- EMA 50
- $1.46
- Price below EMA 50
- SMA 200
- $1.78
- Price below SMA 200
- EMA 200
- $1.79
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 1 analyst rating
Strong Sell0
Sell0
Hold0
Buy1
Strong Buy0
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Revenue
Net income
Net margin %
2021
2022
2023
2024
2025
1M7072563536280
Debt & Balance Sheet
Total assets
Total liabilities
2021
2022
2023
2024
2025
622M410M205M0
Revenue to Profit
2025$893000.0
Revenue$0.0
Cost of revenue$893000.0
Gross profit$0.0
Operating expenses$-69.0M
Net incomeEarnings
No data available
Source: third-party data provider
Latest news

Zacks Investment Research
ProKidney Corp. (PROK) Reports Q2 Loss, Misses Revenue Estimates
PROKAugust 10, 2026
Zacks Investment Research
ProKidney Corp. (PROK) Reports Q2 Loss, Misses Revenue Estimates
PROK

Zacks Investment Research
ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates
PROKMay 15, 2026
Zacks Investment Research
ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates
PROK

Zacks Investment Research
Best Momentum Stocks to Buy for July 17th
PROKJuly 17, 2025
Zacks Investment Research
Best Momentum Stocks to Buy for July 17th
PROK

Zacks Investment Research
New Strong Buy Stocks for July 17th
PROKJuly 17, 2025
Zacks Investment Research
New Strong Buy Stocks for July 17th
PROK

InvestorPlace
7 Penny Stocks With Low Floats and High Short Interest
PROKNovember 24, 2023
InvestorPlace
7 Penny Stocks With Low Floats and High Short Interest
PROK

Finbold
Short squeeze alert for September 27th: 2 stocks that could skyrocket
PROKSeptember 27, 2023
Finbold
Short squeeze alert for September 27th: 2 stocks that could skyrocket
PROK

Finbold
Short squeeze alert for September 4th: Two stocks with potential to skyrocket
PROKSeptember 4, 2023
Finbold
Short squeeze alert for September 4th: Two stocks with potential to skyrocket
PROK

InvestorPlace
3 Biotech Stocks Due for a Massive Short Squeeze
PROKAugust 31, 2023
InvestorPlace
3 Biotech Stocks Due for a Massive Short Squeeze
PROK
About ProKidney Corp. Class A Ordinary Shares
No description available.
SectorHealthcare
IndustryBiotechnology
Employees231
CEODr. Bruce Culleton M.D.
IPO DateJul 12, 2022
HeadquartersWinston-Salem, NC
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Bruce Culleton M.D. | CEO & Director | 1969 |
| Mr. James Coulston CPA | Chief Financial Officer | 1977 |
| Mr. Todd C. Girolamo Esq., J.D., M.B.A. | Chief Legal Officer & Secretary | 1965 |
| Mr. Kenneth Locke | Chief Technical Officer | — |
| Mr. Richard Williams | Chief Information Officer | — |
| Ms. Carla Poulson | Chief People Officer | — |
| Dr. Joseph M. Stavas M.D., M.P.H. | Senior Vice President of Interventional Procedures | — |
| Dr. Darin J. Weber Ph.D. | Chief Reg. Off, SVP and Head of Global Reg. Affairs, Quality Mgmt, Biometrics & Market Access | 1968 |
| Dr. Emily Butler Ph.D. | Senior VP of Biometric | — |
| Mr. Gregory P. Madison | Chief Commercial Officer | 1967 |
Fundamentals
Valuation
Price-to-sales ratio1,096.73
Price-to-book value-0.38
Profitability
Return on Equity9.00%
Return on Assets-27.00%
Return on Sales-10411.00%
Gross margin (latest quarter)100.00%
EBITDA$-78.32M
Trading
Average volume1,448,634
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 36.51
- MACD 12/26/9
- -0.13
- EMA 9 of MACD
- -0.12
- MACD histogram
- -0.01
- SMA 50
- $1.56
- Price below SMA 50
- EMA 50
- $1.46
- Price below EMA 50
- SMA 200
- $1.78
- Price below SMA 200
- EMA 200
- $1.79
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
Analyst consensus:Buy
100% Buy
0% Hold
0% Sell
Analyst price target
- Low
- $8.00
- Average
- $8.00
- High
- $8.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022 | +14.0 | -3.4 | -6.8 | +8.8 | -13.2 | -33.1 | ||||||
| 2023 | +51.8 | +11.8 | -2.2 | -15.0 | +18.2 | -0.2 | +11.8 | -34.4 | -47.0 | -62.1 | +0.6 | +5.3 |
| 2024 | -23.4 | +26.4 | +1.9 | +29.4 | +61.1 | -18.8 | -6.4 | +10.1 | -20.0 | -6.4 | +29.0 | -20.7 |
| 2025 | -4.6 | -20.6 | -20.0 | +7.2 | -15.3 | -21.3 | +386.0 | -16.3 | +5.2 | +17.7 | -22.1 | -0.9 |
| 2026 | -11.2 | +9.8 | -22.5 | +8.6 | -5.2 | +10.3 | -18.5 | +21.2 | -10.3 | -24.0 | +0.9 |
Compare stocks
Market cap
$236.14M
-
-
-
Price / Earnings ratio
-4.00
-
-
-
Price / Sales ratio
1,096.73
-
-
-
Dividend yield
0.00%
-
-
-
Average volume
1,448,634
-
-
-
Earnings per share
$-0.55
-
-
-



